For Release: December 7, 2006
Refer to: Sharon Corbitt
Office: (317) 277-1574
Mobile: (317) 997-1206
E-mail: corbittsd@lilly.com
Eli Lilly and Company Submits New Drug Application for EVISTA for Reduction of
Invasive Breast Cancer Risk in Postmenopausal Women
Submission Is Largest In Lilly History, Including Data From Approximately
37,000 Women
INDIANAPOLIS, IN - Eli Lilly and Company (NYSE: LLY) announced today that it
submitted a New Drug Application (NDA) to the U.S.
Most Popular
10 Jobs That Pay $30 An Hour
13 Job Interview Mistakes To Avoid
3 Questions No Job Seeker Ever Wants To Be Asked?
Public Speaking: 7 Secrets Of Great Public Speakers
Employee Incentive Program - Getting The Best Value For Money
Food and Drug
Administration’s Division of Drug …
Read the rest of this article with a Free Trial at HighBeam Research.